Related Experiment Video

Updated: Mar 7, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.4K

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Longchuan Bai1,2, Bing Zhou1,2, Chao-Yie Yang1,2

  • 1University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.

Cancer Research
|February 18, 2017
PubMed

Insights

A new drug, BETd-246, effectively targets and degrades BET proteins in triple-negative breast cancer (TNBC) cells. This targeted degradation shows superior potency and antitumor activity, offering a promising new therapeutic strategy for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Triple-negative breast cancer (TNBC) presents significant clinical challenges due to limited targeted therapy options.
  • BET proteins are implicated in cancer progression and represent a potential therapeutic target.

Purpose of the Study:

  • To develop and evaluate a second-generation BET protein degrader, BETd-246, for its efficacy against TNBC.
  • To investigate the molecular mechanisms underlying BETd-246's antitumor activity.

Main Methods:

  • Development of BETd-246, a selective BET protein degrader.
  • In vitro studies using human TNBC cell lines to assess protein degradation, growth inhibition, and apoptosis.
  • RNA-sequencing (RNA-seq) to analyze gene expression changes.
  • In vivo studies using murine xenograft models of human breast cancer.

Main Results:

  • BETd-246 induced rapid and potent degradation of BET proteins in TNBC cells at nanomolar concentrations.
  • BETd-246 demonstrated superior growth inhibition and apoptosis induction compared to a parental BET inhibitor.
  • RNA-seq revealed significant downregulation of proliferation-related genes and modulation of apoptosis pathways.
  • The MCL1 gene was identified as a key downstream mediator, showing synergy with BCL-xL inhibitors.
  • In vivo studies confirmed BETd-246 and its analogue BETd-260 achieved significant tumor regression with good tolerability.

Conclusions:

  • Targeting BET proteins for degradation is a viable and effective therapeutic strategy for TNBC.
  • BETd-246 exhibits potent preclinical activity and warrants further investigation for TNBC treatment.
  • The identified downstream effectors provide insights into the mechanism of action for BET degraders.

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60